Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2009-05-12
2010-11-23
Reddig, Peter J (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C435S325000, C435S252300, C435S252330, C435S320100
Reexamination Certificate
active
07838648
ABSTRACT:
The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.
REFERENCES:
patent: 5532348 (1996-07-01), Huibregise et al.
patent: 5912143 (1999-06-01), Bandman et al.
patent: 6451979 (2002-09-01), Kaelin
patent: 0 377 295 (1990-07-01), None
patent: WO94/01563 (1994-01-01), None
patent: WO94/08241 (1994-04-01), None
patent: WO99/66946 (1999-12-01), None
Matsushita et al. (FEBS Letters, 1999, vol. 443, pp. 348-352).
Singh et al. (Glycobiology, 2001, vol. 11, pp. 587-592).
Alberts et al., Molecular Biology of the Cell, 3rd ed., 1994, p. 465.
Arai et al., Immunologically distinct p53 molecules generated by alternative splicing, Mol. Cell. Biol., Sep. 1986, vol. 6. No. 9, pp. 3232-3239.
B. Curti, Physical barriers to drug delivery in tumors, Critical Reviews in Oncology/Hematology, 1993, pp. 29-39.
Benedict et al., The Long Isoform of Termainal Deoxynucleotidyl Transferase Enters the Nucleus and, Rather than Catalyzing Nontemplated Nucleotide . . . , J. of Exp. Medicine, 2001, vol. 193, No. 1., pp. 89-99.
Bodrug et al., Molecular analysis of a constitutional X-autosome translocation in a female with muscular dystrophy, Science, vol. 237, 1987, pp. 1620-1624.
Bork, P., Powers and Pitfalls in Sequence Analysis: The 70% Hurdle, Genome Research, 2000, vol. 10, pp. 398-400.
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, Science, 1990, vol. 247, pp. 1306-1310.
Burgess et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. of Cell Bio. 1990, vol. 111, pp. 2129-2138.
Dequiedt et al., DNA Seq. 5, 1995, pp. 255-259.
Dequiedt et al., See Score 20060927—162151—us-11-122-636-6—copy—110—310.rup database Sequence search, Result 38, DNA Seq, 1995,5: 261-264.
Frasca et al., p73 Tumor-Suppressor Activity Is Impaired in Human Thyroid Cancer, Cancer Research, vol. 63, Sep. 15, 2003, pp. 5829-5837.
Fu et al., Translational regulation of human p53 g in Expression, EMBO Journal, 1996, vol. 15, pp. 4392-4401.
H. Drexler, Recent Results on the Biology of Hodgkin and Reed-Sternberg cells, Leukemia and Lymphoma, 1993, vol. 9, pp. 1-25.
Hartwell et al., Integrating Genetic Approaches into the Discovery of Anticancer Drugs, Science, Nov. 7, 1997, vol. 278, pp. 1064-1068.
Hirashima et al., Ecalectin/Galectin-9, a Novel Eosinophil Chemoattractant: Its Function and Production. Int. Arch. Allergy Immunol., 2000, Suppl. 1, pp. 6-9.
Ichimiya et al., p73: Structure and Function, Pathol Int. Aug. 2000, vol. 50, No. 8, pp. 589-593.
Ikawa et al., p53 family genes: structural comparison, expression and mutation, Cell Death and Differentiation, 1999, vol. 6, pp. 1154-1161.
Iwase et al., Identification of protein-tyrosine kinase gnes preferentially expressed in embryo stomach and gastric cancer, Biochem Biophys Res. Commun.
Jansen et al., Translational Control of Gene Expression, Pediatric Res. 1995, vol. 37, No. 6, pp. 681-686.
Jiang et al., Smooth Muscle Tissues Express a Major Dominant Negative Spice Varian of the Type 3 Ca2′ Release Channel (Ryanodine Receptor), J. of Bio. Chem., 2003, vol. 278, No. 7, pp. 4763-4769.
Kaghad et al., Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers, Cell, Aug. 22, 1997, vol. 90, pp. 809-819.
Lazar et al., Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. & Cell. Biol., Mar. 1988, vol. 8, No. 3, pp. 1247-1252.
M. Embleton, Monoclonal Antibodies to Osteogenic Sarcoma Antigens, Immunol. Ser. 1984, pp. 181-207.
McClean et al., Evidence of Post-translational Regulation of P-Glycoprotein Associated with the Expression of a Distinctive Multiple Drug-resistant Phenotype in Chinese Hamster Ovary Cells, Eur. J. Cancer, 1993, vol. 29A, pp. 2243-2248.
Neumann et al., Multifactorial inheritance of neural tube defects: localization of the major gene and recognition of modifiers in ct mutant mice, Nature Genetics, 1994, vol. 6, pp. 357-362.
P. Bork, Powers and Pitfalls in Sequence Analysis: the 70% Hurdle, Genome Research, 2000, vol. 10, pp. 398-400.
Puig et al., p73 Expressio in Human Normal and Tumor Tissues: Loss of p73 alpa Expression is Associated with Tumor Progession in Bladder Cancer, Cancer Research, Nov. 15, 2003, vol. 9, pp. 5652-5651.
R. Jain, Barriers to Drug Delivery in Solid Tumors, Scientific American, Jul. 1994, pp. 58-65.
Scott et al., The Pendered syndrom gene encodes a chloride-iodide transport protein, Nature Genetics, 1999, vol. 21, pp. 440-443.
Shantz et al., Translational regulation of omithine decarboxylase and other enzymes of the polyamine pathway, Int. J. Biochem and Cell Biol. 1999, vol. 31, pp. 107-122.
Soussi et al., Nucleotide sequence of a cDNA encoding the chicken p53 nuclear protein, Nucleic Acid Research, 1998, vol. 16, No. 23, p. 1183.
T. Gura, Systems for Identifying New Drugs Are Often Faulty, Science, Nov. 7, 1997, vol. 278, pp. 1041-1042.
T.C. Hsu, Karyology of Cells in Culture, Tissue Culture Methods and Applications, Kruse and Patterson Eds. 1973, Academic Press, NY, see abstract p. 764.
Tominaga et al., Detection of p73 antibodies in patients with various types of cancer: immunological characterization, Br. J. of Cancer, 2001, vol. 84, No. 1, pp. 57-63.
Wilson et al., 2.2 Mb of continguous nucleotide sequence from chromosome III of C. elegans, Nature, vol. 368, pp. 32-38.
Zellner et al., Disparity in Expression of Protein Kinase C alpha in Human Glioma versus Glioma-derived Primary Cell Lines: Therapeutic Implications, Clin. Can. Res. 1998, vol. 4, pp. 1797-1802.
Caput Daniel
Ferrara Pascual
Kaghad Ahmed Mourad
Reddig Peter J
Sanofi - Aventis
LandOfFree
Purified SR-p70 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified SR-p70 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified SR-p70 protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236763